Industries > Pharma > Cancer Biologics Market Report 2021-2031

Cancer Biologics Market Report 2021-2031

Forecasts by Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), by Indication (Breast Cancer, Cervical Cancer, Colon and Rectal Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Renal Cell Cancer, Melanoma), by Biologic Drugs (Bevacizumab, Trastuzumab, Trastuzumab Emtansine, Pertuzumab, Rituximab, Cetuximab, Panitumumab, Ramucirumab, Necitumumab, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Ipilimumab), by End-user (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cancer Biologics Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 04 February 2021
PAGES: 363
PRODUCT CODE: PHA1016

Clear
WOOCS 2.2.1
SKU: PHA1016 Categories: , , Tag:

This report is intended to provide an in-depth analysis of the latest trends prevailing in the cancer biologics market and its growth and development in the next decade. The changing demographics of the world population, increasing cancer prevalence, developing healthcare infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.

Why Cancer Biologics Market is Growing?
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies. Moreover, rising number of pre-screening programs for cancer detection using liquid biopsy are expected to provide new market opportunities for cancer biologics in near future.

What are the Market Driving Factors?
• Rising Cancer Prevalence Worldwide
• Increasing Ageing Population in Developed as well as Developing Economies

Key Challenges for Cancer Biologics Market
• Shortage of Skilled Workforce in the Biopharmaceutical Industry
• High Cost Associated with Biopharmaceutical Drug Manufacturing

What are the Market Opportunities?
• Increasing R&D Spending of Biopharmaceutical Companies
• Future Perspective in Oncology Industry

Why you Should buy this Report?
Apart from market estimation and forecast to 2031 the report covers below mentioned important factors to offer in-depth analysis of cancer biologics industry
• SWOT Analysis
• Porter’s Five Forces Model
• European Oncology Market Trends
• Global Oncology Spending, 2016 – 2031
• Disease Prevalence and Incidence in Europe by Country
• EMA Approved Biologics in Oncology
• Biosimilars and R&D Biologics in Development

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

What are the Leading Companies Operating in the Market?
• AbbVie Inc
• F.Hoffman La Roche
• GlaxoSmithKline
• Eli Lilly and Company
• Amgen
• Johnson & Johnson
• Merck & Co.
• Pfizer

CTA

Market Segmentation and Scope

Cancer Biologics Market by Treatment
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Others

Cancer Biologics Market by Indication
• Breast cancer
• Cervical cancer
• Colon and rectal cancer
• Gastric cancer
• Lung cancer
• Ovarian cancer
• Renal cell cancer
• Melanoma

Cancer Biologics Market by Biologic Drug
• Bevacizumab
• Trastuzumab
• Trastuzumab emtansine
• Pertuzumab
• Rituximab
• Cetuximab
• Panitumumab
• Ramucirumab
• Necitumumab
• Pembrolizumab
• Atezolizumab
• Durvalumab
• Nivolumab
• Ipilimumab

Cancer Biologics Market by End User
• Hospitals
• Specialty Clinics
• Cancer and Radiation Therapy Centers

Europe Cancer Biologics Market
• UK Cancer Biologics Market
• Germany Cancer Biologics Market
• France Cancer Biologics Market
• Italy Cancer Biologics Market
• Spain Cancer Biologics Market
• Portugal Cancer Biologics Market
• Poland Cancer Biologics Market
• Hungary Cancer Biologics Market
• Czech Republic Cancer Biologics Market
• Slovakia Cancer Biologics Market
• Slovenia Cancer Biologics Market
• Romania Cancer Biologics Market
• Bulgaria Cancer Biologics Market
• Croatia Cancer Biologics Market
• Baltic States Cancer Biologics Market
• Serbia Cancer Biologics Market

Cancer Biologics Market Report 2021-2031

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Cancer Biologics Market Report 2021-2031: Forecasts by Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), by Indication (Breast Cancer, Cervical Cancer, Colon and Rectal Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Renal Cell Cancer, Melanoma), by Biologic Drugs (Bevacizumab, Trastuzumab, Trastuzumab Emtansine, Pertuzumab, Rituximab, Cetuximab, Panitumumab, Ramucirumab, Necitumumab, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Ipilimumab), by End-user (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cancer Biologics Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Cancer Biologics Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Cancer Biologics Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Rare Diseases Market Report 2021-2031

As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

02 March 2021

READ

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

READ

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

READ

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

READ

Categories